Close

Dr Daniela Manno

Clinical Assistant Professor

London School of Hygiene & Tropical Medicine
Keppel Street
London
WC1E 7HT
United Kingdom

I am a clinical epidemiologist with extensive expertise in infectious diseases and clinical trials, particularly in the field of vaccine research for outbreak-prone infectious diseases. My PhD work, which involved assessing the safety and immunogenicity of the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen against Ebola virus disease (EVD) in Sierra Leone, provided me with critical insights into the complexities of vaccine research for emerging infections.

Additionally, I served as the responsible physician for the London School of Hygiene & Tropical Medicine (LSHTM) during a large-scale vaccine trial in the Democratic Republic of Congo (DRC) that administered the Ad26.ZEBOV and MVA-BN-Filo regimen to over 20,000 adults and children, including pregnant women, during the 2018-2020 EVD outbreak in North Kivu and Ituri provinces. I also coordinated a follow-up study on participants vaccinated with the same vaccine regimen in Sierra Leone (NCT03820739) and, as a co-principal investigator at LSHTM, led a safety follow-up study with a similar cohort in Tanzania, securing funding of €145,967 (NCT02661464).

My current interests focus on improving the inclusion of pregnant and breastfeeding women in vaccine research for emerging infections to enhance the safety of these women and their babies during health emergencies. Additionally, I am involved in projects investigating Lassa fever epidemiology in Sierra Leone and summarising the evidence on the effectiveness of single-dose vaccination for Human Papilloma Virus (HPV).

Affiliations

Department of Clinical Research
Faculty of Infectious and Tropical Diseases

Centres

Centre for Epidemic Preparedness and Response
Centre for Maternal Adolescent Reproductive & Child Health

Teaching

I am a tutor and marker for the modules 'Applying Public Health Principles in Developing Countries' (3198) and ‘Control of Sexually Transmitted Infections’ (3192). Additionally, I facilitate the Decolonising Global Health (DGH) talks for the Diploma in Tropical Medicine and Hygiene (DTM&H 2024).

Research

My primary research interests centre on conducting clinical trials and other epidemiological studies in the field of infectious diseases and vaccines. Currently, I am particularly focused on improving the inclusion of pregnant and breastfeeding women in vaccine research for emerging infections, with the aim of enhancing the safety of these women and their babies during health emergencies. Additionally, I am involved in projects investigating Lassa fever epidemiology in Sierra Leone and summarising the evidence on the effectiveness of single-dose vaccination for HPV.

Research Area
Epidemiology
Clinical trials
Vaccines
Maternal health
Outbreaks
Disease and Health Conditions
Ebola virus
Malaria
Lassa fever
Human papillomavirus (HPV)
Country
Sierra Leone
Tanzania
Democratic Republic of the Congo
Nigeria
Region
Sub-Saharan Africa (all income levels)

Selected Publications

Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.
Puri, A; Pollard, AJ; Schmidt-Mutter, C; Lainé, F; PrayGod, G; Kibuuka, H; Barry, H; Nicolas, J-F; Lelièvre, J-D; Sirima, SB; Kamala, B; MANNO, D; WATSON-JONES, D; Gaddah, A; Keshinro, B; Luhn, K; Robinson, C; Douoguih, M; EBL4001 Study Group,;
2024
Vaccines
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Man-Lik Choi, E; Abu-Baker Mustapher, G; Omosa-Manyonyi, G; Foster, J; Anywaine, Z; Musila Mutua, M; AYIEKO, P; Vudriko, T; Ann Mwangi, I; Njie, Y; Ayoub, K; Mundia Muriuki, M; Kasonia, K; Edward Connor, N; Florence, N; MANNO, D; Katwere, M; McLean, C; Gaddah, A; Luhn, K; Lowe, B; GREENWOOD, B; Robinson, C; Anzala, O; KALEEBU, P; ... EBL2010 Study Team,
2023
Vaccine
Developing a vaccine against Sudan virus disease.
MANNO, D;
2023
The Lancet. Infectious diseases
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.
MANNO, D; PATTERSON, C; Drammeh, A; TETTEH, K; KROMA, MT; Otieno, GT; Lawal, BJ; SOREMEKUN, S; AYIEKO, P; Gaddah, A; Kamara, AB; Baiden, F; AFOLABI, MO; TINDANBIL, D; Owusu-Kyei, K; Ishola, D; Deen, GF; Keshinro, B; Njie, Y; Samai, M; Lowe, B; Robinson, C; Leigh, B; DRAKELEY, C; GREENWOOD, B; ... WATSON-JONES, D.
2023
Vaccines
Developing a vaccine against Marburg virus disease.
MANNO, D;
2023
Lancet (London, England)
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
MANNO, D; Bangura, A; Baiden, F; Kamara, AB; AYIEKO, P; Kallon, J; Foster, J; Conteh, M; CONNOR, NE; Koroma, B; Njie, Y; Borboh, P; Keshinro, B; Lawal, BJ; KROMA, MT; Otieno, GT; Deen, AT; CHOI, EM-L; BALAMI, AD; Gaddah, A; McLean, C; Luhn, K; Adetola, HH; Deen, GF; Samai, M; ... WATSON-JONES, D.
2022
The Lancet. Infectious diseases
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone.
MANNO, D; AYIEKO, P; Ishola, D; AFOLABI, MO; Rogers, B; Baiden, F; Serry-Bangura, A; Bah, OM; Köhn, B; Swaray, I; Owusu-Kyei, K; Otieno, GT; Kowuor, D; TINDANBIL, D; Smout, E; Robinson, C; Keshinro, B; Foster, J; GALLAGHER, K; Lowe, B; Douoguih, M; Leigh, B; GREENWOOD, B; WATSON-JONES, D;
2022
Emerging Infectious Diseases
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
AFOLABI, MO; ISHOLA, D; MANNO, D; Keshinro, B; Bockstal, V; Rogers, B; Owusu-Kyei, K; Serry-Bangura, A; Swaray, I; Lowe, B; Kowuor, D; Baiden, F; Mooney, T; Smout, E; Köhn, B; Otieno, GT; Jusu, M; Foster, J; Samai, M; Deen, GF; LARSON, H; LEES, S; Goldstein, N; Gallagher, KE; Gaddah, A; ... EBL3001 study group,
2021
Lancet Infectious Diseases
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
ISHOLA, D; MANNO, D; AFOLABI, MO; Keshinro, B; Bockstal, V; Rogers, B; Owusu-Kyei, K; Serry-Bangura, A; Swaray, I; Lowe, B; Kowuor, D; BAIDEN, F; Mooney, T; Smout, E; Köhn, B; Otieno, GT; Jusu, M; Foster, J; Samai, M; Deen, GF; LARSON, H; LEES, S; Goldstein, N; Gallagher, KE; Gaddah, A; ... EBL3001 study group,
2021
Lancet Infectious Diseases
See more information